AMOÉBA announces the availability of the 2020 Universal Registration Document
including the Annual Financial Report
Lyon (France), April 12, 2021 -5.45 pm- AMOÉBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating bacterial risk in water
and human wounds, and a biocontrol product for plant protection, still in a
development phase, announces that the 2020 Universal Registration Document was
filed with the French Financial Markets Authority (Autorité des marchés
financiers- AMF) on April 12, 2021 under number D.21-0289.
The document may be viewed or downloaded on the company's website
www.amoeba-nature.com under section "Investors / financial documents/ Reference
Document". Copies of the Universal Registration Document are also available at
the company's headquarters: 38, avenue des frères Montgolfier, 69680 Chassieu,
The 2020 Universal Registration Document includes:
- the Annual Financial Report comprising the consolidated financial statements,
the parent company financial statements, the management report and the related
statutory auditors' reports
- the Board of Directors' corporate governance report.
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK